Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.51 |
| ▸ | DPP4 | P27487 | 4/20 | 0.51 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28295881 | 1.00 | NOD1 (0.53) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL28295882 | 1.00 | NOD1 (0.53) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL31433224 | 0.94 | NOD1 (0.55) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL31433288 | 0.93 | NOD1 (0.48) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL31433194 | 0.92 | NOD1 (0.47) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL29382412 | 0.89 | NOD1 (0.55) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL2850058 | 0.89 | DPP7 (0.58) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL29376792 | 0.89 | DPP7 (0.58) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL8495657 | 0.88 | DPP4 (0.54) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL8497101 | 0.87 | DPP7 (0.57) | NOD1DPP8DPP9DPP7DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
| US-7977306-B2 | Albumin fusion proteins | HUMAN GENOME SCIENCES, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20080293629-A1 | Albumin Fusion Proteins | HUMAN GENOME SCIENCES, INC. | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | NOD1 2061/4885DPP8 204/4885DPP9 408/4885 |
| US-20080293629-A1 | Albumin Fusion Proteins | ALB, FABP1, IAPP | NOD1 972/4885DPP8 392/4885DPP9 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.